Osman Farooq
Neurology · Buffalo, NYNPI 1700034196
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Livanova USA, Inc. accounts for 70.5% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $5,458, 5.3 times the $1,022 reported in 2019.
Across 249 payments — averaging $64.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$11K
- UCB, Inc.$1K
- Biogen$843
- Jazz Pharmaceuticals Inc.$676
- Pyros Pharmaceuticals, Inc.$482
- SK Life Science, Inc.$411
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$8,58053%
- Travel & lodging$2351%
- Food & beverage$7,30745%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 107 | $11,369 |
| UCB, Inc. | 45 | $1,250 |
| Biogen | 29 | $843 |
| Jazz Pharmaceuticals Inc. | 18 | $676 |
| Pyros Pharmaceuticals, Inc. | 2 | $482 |
| SK Life Science, Inc. | 10 | $411 |
| Mallinckrodt Enterprises LLC | 3 | $232 |
| Neurelis, Inc. | 10 | $176 |
| Acadia Pharmaceuticals Inc | 7 | $141 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $100 |
| Upsher-smith Laboratories LLC | 3 | $87 |
| Teva Pharmaceuticals USA, Inc. | 1 | $86 |
| ITF Therapeutics LLC | 2 | $53 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Supernus Pharmaceuticals, Inc. | 3 | $40 |
| CSL Behring | 1 | $35 |
| PTC Therapeutics, Inc. | 2 | $32 |
| Novartis | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Biomarin Pharmaceutical Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$7,487
- VNS - Sentiva$1,700
- VIGPODER$482
- VNS Therapy$464
- Epidiolex$289
- SPINRAZA$230
- ACTHAR$125
- XCOPRI$125
- Fintepla$125
How this compares
$16,123 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 19 | $188,743 |
| BanzelRufinamide | 11 | $66,176 |
| Lacosamide | 35 | $2,781 |
| Levetiracetam | 16 | $1,462 |
| Zonisamide | 43 | $1,105 |
| Lamotrigine | 37 | $520 |
Paid to pharmacies, not to this prescriber.
Other neurology in Buffalo
- Gil WolfeBuffalo$617K
- David HojnackiBuffalo$480K
- Bianca Weinstock GuttmanBuffalo$288K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.